Back to Search
Start Over
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
- Source :
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS722-TPS722, 193p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 42
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 175074480
- Full Text :
- https://doi.org/10.1200/JCO.2024.42.4_suppl.TPS722